Maximum androgen blockade (MAB) v androgen suppression (AS) alone for overall survival at 5 years in advanced prostate cancer (individual patient data from 27 trials)*

MAB (all 3 drugs)ASABI(95% CI)RBINNT (CI)
25.4%23.6%1.8%(−0.7 to 4.3)7.6%Not significant
MAB (nilutamide or flutamide)
27.6%24.7%2.9%(0.4 to 5.4)11.7%35(19 to 250)
MAB (cyproterone acetate)ABR (CI)RBRNNH
*ABR = absolute benefit reduction; RBR = relative benefit reduction. Other abbreviations defined in glossary; RBI, RBR, NNT, NNH, and CI calculated from data in article.
15.4%18.1%2.8%(−1.9 to 7.5)15%Not significant